Day: March 16, 2026

Nantes, France, March 16, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its financial calendar for 2026.  Information Date* 2025 Full-Year Financial Update and Statements April 29, 20262026 1Q Cash Position April 30, 2026Annual General Meeting June 24, 20262026 First-Half Financial Update and Statements September 28, 20262026 3Q Cash Position October 27, 20262026 4Q Cash Position January 26, 2027* This financial calendar is provided for information only and may be subject to changes. The Company’s updated financial calendar is available on its corporate website.ABOUT OSE IMMUNOTHERAPEUTICSOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet...

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 301,322 944.05 284,461,7499 March 2026 16,631 884.02 14,702,18010 March 2026 16,134 912.72 14,725,80411 March 2026 15,816 904.61 14,307,23712...

EfTEN United Property Fund earned a net profit of 131 thousand euros in February 354 thousand euros in first two months of 2026 (the same period last year: 525 thousand euros). The net asset value (NAV) of the fund unit was 11,9 euros at the end of February, increasing by 0,4% per month. Invego Uus-Järveküla OÜ, a development company in which the fund has an 80% stake, concluded 12 real rights contracts in February and clients booked 2 terraced houses. As of the end of the month, a total of 8 terraced houses had not yet been reserved by clients. In February, EfTEN United Property Fund earned 17 thousand euros in interest income from the investment and the development company earned 615 thousand euros of profit. As EfTEN United Property Fund values all equity investments at fair value, the February profit from the Uus-Järveküla development...

Press contactFahd PashaTel.: +1 647 860 3777Fahd.Pasha@capgemini.com 85% of banks’ corporate clients plan to engage with a non-bank financial institution within the next year as competition with private capital intensifiesBanks look to bolster AI expertise with external hires (40%) as upskilling proves challenging Only 29% of IT budgets are currently directed to transformative technologies Corporate Investment Banks executives bet on tokenized products (51%) to improve performanceParis, March 16, 2026 – Corporate and investment banks (CIBs) are facing intense competition from non‑bank financial institutions, as client expectations rise and technology initiatives fail to deliver the anticipated benefits, according to the Capgemini Research Institute’s inaugural World Corporate and Investment Banking Report 2026. The research shows...

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan presents 2025 results and provides details on program to reignite profitable growth Financial results for the full year 2025 – SummarySales of CHF 882.5 million (2024: CHF 934.3 million), down 1.6% in local currencies for the year, with second-half sales growth of 0.4% Order entry increased by 3.8% in local currencies for the full year and by 8.6% in the second half Adjusted EBITDA of CHF 142.1 million (2024: CHF 164.4 million), adjusted EBITDA margin of 16.1% (2024: 17.6%), impacted by adverse foreign exchange effects and tariffs, partly offset by cost-reduction measures and underlying improvements Net profit impacted by non-cash impairment charges of CHF 139.5 million resulting in a reported net loss of CHF 110.7 million (2024: net profit...

BEIJING, March 15, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first healthy volunteer has been dosed in a clinical trial of ICP-538, a VAV1-directed molecular glue degrader (MGD), in China. This is the first VAV1 degrader approved to enter clinical trials in China and the second globally. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key protein downstream of T-cell and B-cell receptors. ICP-538 induces rapid and efficient degradation of VAV1 protein in a dose-dependent manner by selectively mediating the formation of a ternary complex between the CRBN E3 ubiquitin ligase and the VAV1 protein. ICP-538 will be developed for...